Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study

作者：Dalenc Florence; Penault Llorca Frederique; Cohen Monique; Houvenaeghel Gilles; Piat Jean Marc; Liegeois Philippe; Puyuelo Laurent; Suchaud Jean Philippe; Zouai Mohammed; Lacroix Triki Magali; Radosevic Robin Nina; Benkanoun Chahinez; Attar Rabia Hanane; Chauvet Marie Pierre; Gligorov Joseph; Belkacemi Yazid^*

来源：Clinical Breast Cancer, 2017, 17(2): 107-116.

DOI：10.1016/j.clbc.2016.08.007

• Adjuvant treatment
• Breast cancer subtypes
• Conservative surgery
• Endocrine therapy
• Radiotherapy

The subgroup of breast cancer tumors 510 mm requiring adjuvant systemic therapy is currently not well defined. A prospective cohort study was conducted in patients with unifocal, invasive pT1a-b pN0 non-metastatic breast cancer to describe the daily adjuvant management and outcome after surgery. In this study, most patients had conservative surgery followed by radiotherapy and hormone therapy; however the benefit of adjuvant chemotherapy with or without trastuzumab remains controversial.
Background: Most breast cancer (BC) tumors <= 10 mm have an excellent prognosis. The subgroups with a higher risk for distant recurrence requiring adjuvant systemic therapy are not precisely defined in current international guidelines. Patients and Methods: The OBSERVATOIRE DES PETITS CANCERS DU SEIN HER2 +/- (ODISSEE) study was a prospective, multicenter, cohort study that aimed to describe the daily adjuvant management and outcome of 616 patients with unifocal, invasive pT1a-b pN0 nonmetastatic BC who underwent surgery. Results: At the time of diagnosis, the median age of patients was 61 years. Tumor was detected on imaging or during a screening program in 397 patients (64.6%). Most patients (96%) underwent conservative surgery with sentinel node biopsy (89%), completed with axillary lymph node dissection in 15%. At inclusion, 82% of tumors were pT1b, 73% were pN0 (i-), 53% were Scarff Bloom Richardson Grade I, 91 % were estrogen receptor (ER)-positive, 5% overexpressed/amplified HER2, and 5% were triple negative (TNBC). Adjuvant treatments were radiotherapy (95%), hormone therapy (82%), chemotherapy (7%), and trastuzumab (3.5%). In patients with TNBC and HER2-positive BC, chemotherapy and trastuzumab (if needed) were administered in 45% and 68%, respectively. After 5 years of follow-up, 7 patients had contralateral BC, 7 had locoregional recurrence, and 1 had distant metastasis. At 5 years, overall survival, disease-free survival, and recurrence-free survival were: 98.4% (96.9%-99.1%), 94.7% (92.4%-96.3%), and 97.1 % (95.2%-98.2%), respectively. Conclusion: This prospective cohort study showed that in France, the routine practice in pT1a-b pN0 breast cancers follows international standard guidelines for practice including conservative surgery followed by radiotherapy and endocrine therapy for ER -positive patients. Adjuvant chemotherapy with or without trastuzumab was used but their benefit in breast cancer of <= 10 mm remains controversial.

• 出版日期2017-4